{"organizations": [], "uuid": "2c9e40fbc18b59f5ee3aa83ddb959c0dc98efdbe", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-intellia-therapeutics-inc-q1-loss/brief-intellia-therapeutics-inc-q1-loss-per-share-0-51-idUSASC09YJU", "country": "US", "domain_rank": 408, "title": "BRIEF-Intellia Therapeutics Inc Q1 Loss Per Share $0.51", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T14:34:00.000+03:00", "replies_count": 0, "uuid": "2c9e40fbc18b59f5ee3aa83ddb959c0dc98efdbe"}, "author": "", "url": "https://www.reuters.com/article/brief-intellia-therapeutics-inc-q1-loss/brief-intellia-therapeutics-inc-q1-loss-per-share-0-51-idUSASC09YJU", "ord_in_thread": 0, "title": "BRIEF-Intellia Therapeutics Inc Q1 Loss Per Share $0.51", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-intellia therapeutics inc", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "intellia therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 11:36 AM / Updated 5 minutes ago BRIEF-Intellia Therapeutics Inc Q1 Loss Per Share $0.51 Reuters Staff\nMay 1 (Reuters) - Intellia Therapeutics Inc:\n* INTELLIA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS\n* ANTICIPATES SUBMITTING ITS IN VIVO INVESTIGATIONAL NEW DRUG APPLICATION BY END OF 2019 * QTRLY LOSS PER SHARE $0.51\n* $328 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018\n* CONFIRMS PLANS TO INITIATE IND-ENABLING STUDIES IN MID-2018 FOR ITS LEAD INDICATION, TRANSTHYRETIN AMYLOIDOSIS\n* INTELLIA PLANS TO SHARE PRECLINICAL DATA ON BOTH IMMUNO-ONCOLOGY AND AUTOIMMUNE DISEASE TARGETS IN 2018\n* COLLABORATION REVENUE WAS $7.5 MILLION FOR Q1 OF 2018, COMPARED TO $6.2 MILLION DURING Q1 OF 2017\n* Q1 EARNINGS PER SHARE VIEW $-0.58, REVENUE VIEW $6.3 MILLION â€” THOMSON REUTERS I/B/E/S\n* INTELLIA - EXPECTS CASH, CASH EQUIVALENTS AS OF MARCH 31, 2018 WILL ENABLE CO TO FUND OPERATING EXPENSES AND CAPEX THROUGH MID-2020 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-01T14:34:00.000+03:00", "crawled": "2018-05-01T14:57:12.000+03:00", "highlightTitle": ""}